Want to see TSE:RVV full AI Analyst Report?
RVV Stock Chart & Stats
C$0.02
<C$0.01(20.00%)
At close: 4:00 PM EDT
C$0.02
<C$0.01(20.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.08
Previous CloseN/A
Volume3.00K
Average Volume (3M)285.50K
Market Cap
C$10.46M
Enterprise ValueC$13.12M
Total Cash (Recent Filing)C$22.66K
Total Debt (Recent Filing)C$70.77K
Price to Earnings (P/E)―
Beta-1.51
Next Earnings
Oct 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding418,564,270
10 Day Avg. Volume295,136
30 Day Avg. Volume285,498
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)0.00
P/FCF Ratio-10.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Absolute DebtMinimal reported debt (TTM ~ $71K) materially lowers near-term solvency and interest burdens for a development-stage biotech. This preserves strategic optionality to pursue clinical programs, partnerships, or licensing without being constrained by fixed financial obligations over the next several months.
Focused R&D Pipeline In Psilocybin And Repurposed DrugsA clear, focused therapeutic strategy—psilocybin and repurposed compounds—gives the company definable scientific goals and potential pathways to value (clinical milestones, partnerships, licensing). That concentrated pipeline aligns with a structural growth area in psychedelics therapeutics and can drive durable strategic interest.
Improving Cash Burn And Loss Trend TTMOperating cash outflow narrowed materially to around -$0.16M (TTM) and losses have eased versus peak years. Sustained reduction in cash burn improves runway and reduces immediate financing pressure, making near-term execution on trials or partnerships more feasible without urgent capital raises.
Bears Say
Pre-revenue, No Commercial SalesThe company reports zero revenue and negative gross profit across all reported periods, indicating no commercial product or validated revenue stream. This elevates execution and commercialization risk: progress depends on successful R&D outcomes and external funding rather than operating cash generation.
Negative Shareholders' EquityA negative equity position (~-$4.0M TTM) reflects accumulated losses and weakened balance-sheet resilience. Negative equity can limit financing options, increase creditor/partner scrutiny, and raise the likelihood of equity dilution when new capital is required, constraining strategic flexibility over months ahead.
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow implies the business depends on external capital to fund R&D and operations. That reliance creates recurring financing and dilution risk, and can delay programs if market conditions limit access to capital, a structural constraint lasting beyond short-term windows.
Revive Therapeutics News
RVV FAQ
What was Revive Therapeutics Ltd’s price range in the past 12 months?
Revive Therapeutics Ltd lowest stock price was <C$0.01 and its highest was C$0.08 in the past 12 months.
What is Revive Therapeutics Ltd’s market cap?
Revive Therapeutics Ltd’s market cap is C$10.46M.
When is Revive Therapeutics Ltd’s upcoming earnings report date?
Revive Therapeutics Ltd’s upcoming earnings report date is Oct 26, 2026 which is in 78 days.
How were Revive Therapeutics Ltd’s earnings last quarter?
Revive Therapeutics Ltd released its earnings results on Jun 01, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.
Is Revive Therapeutics Ltd overvalued?
According to Wall Street analysts Revive Therapeutics Ltd’s price is currently Overvalued.
Does Revive Therapeutics Ltd pay dividends?
Revive Therapeutics Ltd does not currently pay dividends.
What is Revive Therapeutics Ltd’s EPS estimate?
Revive Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Revive Therapeutics Ltd have?
Revive Therapeutics Ltd has 418,564,270 shares outstanding.
What happened to Revive Therapeutics Ltd’s price movement after its last earnings report?
Revive Therapeutics Ltd reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revive Therapeutics Ltd?
Currently, no hedge funds are holding shares in TSE:RVV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.